Physician profile
Susan C Stanforth
NPI 1861972689
$5,376.37
in general payments reported to CMS, 2019-2025
41 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $1,976 · 2023: $1,180 · 2024: $559 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.34 |
| Education | $125.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $874.81 | 2021-2024 | Erleada, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $711.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $482.16 | 2021-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $449.41 | 2021-2024 | Imfinzi, Enhertu |
| Lilly USA, LLC | $383.74 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Pfizer INC. | $280.06 | 2021-2025 | |
| Amgen INC. | $211.24 | 2021-2023 | Kyprolis, Nplate, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $181.47 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $172.37 | 2021-2024 | Tazverik, Onivyde, Somatuline Depot |
| Merck Sharp & Dohme LLC | $170.56 | 2022-2024 | Keytruda |
| Daiichi Sankyo INC. | $125.70 | 2023-2025 | Enhertu |
| Seagen INC. | $120.04 | 2022 | |
| Kite Pharma, INC. | $116.56 | 2024-2025 | Yescarta |
| Incyte Corporation | $105.98 | 2021-2023 | Jakafi |
| Abbvie INC. | $97.41 | 2021-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Stanforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.